Radotinib HCl not checked
Il-Yang Pharm. Co., Ltd. · IY5511
FollowEvery change as it happens, and a Monday email
Trials
3 active
4 in total · 1 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).”In the company’s words, NCT03722420 on ClinicalTrials.gov
- Tested for
- Chronic Myeloid Leukemia, Chronic Phase (2 trials), CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome, Parkinson Disease
- Main trialPhase 3
- “This is a Phase III, multi-center, open-label, parallel, 2-arm, randomized study to evaluate the efficacy and safety of radotinib 300 mg Bis In Die(BID) versus imatinib 400 mg Quaque Die(QD). This study will be conducted in Chinese patients with newly diagnosed Ph+ Chronic Myelogenous Leukemia(CML)-Chronic Phase(CP) who are previously untreated for Chronic Myelogenous Leukemia(CML).”In the company’s words, NCT03722420 on ClinicalTrials.gov
- Other names
- SUPECT · Radotinib · IY5511
Other drugs for Chronic Myeloid Leukemia, Chronic Phase
- OlverembatinibAscentage Pharma Group Inc. · Phase 3
- ELVN-001Enliven Therapeutics · Phase 3
- TGRX-678TargetRx · Phase 3
- PonatinibTakeda · Phase 1/2
- EmbibatinibTerns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Phase 1/2
- AsciminibNovartis · Phase 2
Coming up1
- 30 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 3 Mar 2023 | Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) | |
| Phase 3Recruiting | 30 Jun 2027 | A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs | |
| Phase 2Active, not recruiting | 2 Sep 2026 | Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease | |
| Phase 1Completed | 25 Sep 2024 | Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026